Details for Patent: 12,064,430
Which drugs does patent 12,064,430 protect, and when does it expire?
Patent 12,064,430 protects OMCAZIO and is included in one NDA.
This patent has forty-one patent family members in eight countries.
Summary for Patent: 12,064,430
| Title: | Kinase inhibitor salts and compositions thereof |
| Abstract: | The present invention relates to cabozantinib lauryl sulfate salt and methods of use. |
| Inventor(s): | Fang-Yu Liu, K. C. Sung, Chin-Yao Yang, Chi-Cheng Lin, Yi-Hsin Lin, Li Qiao |
| Assignee: | Handa Oncology LLC |
| Application Number: | US18/096,598 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 12,064,430
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-001 | Sep 3, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED RENAL CELL CARCINOMA | ⤷ Start Trial | ||||
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-001 | Sep 3, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB | ⤷ Start Trial | ||||
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-002 | Sep 3, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED RENAL CELL CARCINOMA | ⤷ Start Trial | ||||
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-002 | Sep 3, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB | ⤷ Start Trial | ||||
| Handa Oncol | OMCAZIO | cabozantinib laurylsulfate | CAPSULE;ORAL | 220613-003 | Sep 3, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADVANCED RENAL CELL CARCINOMA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,064,430
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019285066 | ⤷ Start Trial | |||
| Australia | 2024205682 | ⤷ Start Trial | |||
| Australia | 2026201135 | ⤷ Start Trial | |||
| Canada | 3102381 | ⤷ Start Trial | |||
| China | 112423757 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
